874883-18-8

Upstream product

• 16473-35-1 4-(hydroxymethyl)benzyl chloride 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 876-08-4 p-(chloromethyl)benzoyl chloride 

Downstream Products

• 1001026-35-2 methyl 3-{[4-[[(tert-butyldimethylsilyl)oxy]methyl]benzyl]sulfonyl}propanoate 

Relevant academic research and scientific papers

RAC INHIBITORS

The present invention relates to compounds that act as pan-Rac inhibitors, compositions including the compounds, and methods of using the compounds. In particular, the compounds are useful for treating certain cancers such as breast cancer.

Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: Preparation and biological evaluation

The poor compatibility of carrier materials with drugs is one of the main obstacles in the drug encapsulation of nano-drug delivery system (NDDS), hindering the clinical translation of NDDS. In this study, using paclitaxel (PTX) as the insoluble model drug, we conjugated N,N-diethylniacinamide (DENA), a hydrotropic agent of PTX, to the backbone of poly(l-γ-glutamyl-glutamine) (PGG), a water-soluble polymer, to prepare the "hydrotropic polymer" PGG-DENA to improve its compatibility with PTX. By virtue of the hydrotropic effect of the DENA group, PTX was encapsulated by PGG-DENA to obtain the hydrotropic polymeric nanoparticles (PGG-DENA/PTX NPs). PTX-conjugated poly(l-γ-glutamyl-glutamine) acid (PGG-PTX) NPs previously reported were used as the control in the study. The PGG-DENA/PTX NPs showed a z-average hydrodynamic diameter of about 70 nm, and good long-term stability in PBS solution at 4 °C. The cumulative release rate of PTX from PGG-DENA/PTX NPs reached 79.10% at 96 h, while that of PGG-PTX NPs was 22.96%. PGG-DENA/PTX NPs showed significantly increased in vitro cytotoxicity on NCI-H460 lung cancer cells compared with PGG-PTX NPs. The hemolysis study proved that the PGG-DENA/PTX NPs has good biocompatibility. These results indicated that by introducing the hydrotropic agent DENA, the hydrotropic polymer PGG-DENA becomes an effective carrier material of PTX. This study provides a solution to increase the compatibility of carrier materials with insoluble drugs, and also may provide an effective way to develop a series of personalized carrier materials suitable for different insoluble drugs.

HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of pl

HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention relates to compounds of general formula (I), wherein D 1 to D 3, -A-, n, R 1, R 2, Y 1, L and y2 are defined as in claim 1, which have valuable pharmacological propert

SYNTHESIS OF TRITHIOCARBONATES AND ALLYL SULFIDES AND THEIR APPLICATION INTO ADVANCES IN COVALENT ADAPTABLE NETWORKS

Monomers having a C-B-A-B-C structure are disclosed, where A is a core of either trithiocarbonate and allyl sulfide, where B are linker units, and where C are end units. The end units may comprise acrylates, methacrylates, alcohol(s), amine(s), and alkyne

Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. Separation of the antithrombotic effect and bleeding for candidate drug AZD1283

Synthesis and structure-activity relationships of ethyl 6-aminonicotinate acyl sulfonamides, which are potent antagonists of the P2Y12 receptor, are presented. Shifting from 5-chlorothienyl to benzyl sulfonamides significantly increased the pot

NEW PYRIDINE ANALOGUES

The present invention relates to certain new pyridin analogues of Formula ( I ), to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.